CRDL.TO · Cardiol Therapeutics Inc

-

Please sign in to comment on CRDL.TO

1 Comment

Admin

4 years ago

Cardiol Therapeutics Inc is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Cardiol Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 43.9% to $-4M since the same quarter in the previous year.

Finally, its free cash flow grew by 17.4% to $-3M since the same quarter in the previous year.

Based on the above factors, Cardiol Therapeutics Inc gets an overall score of 2/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	TO
CurrencyCode	CAD
ISIN	CA14161Y2006

Beta	0.67
PE Ratio	None
Target Price	11
Market Cap	122M
Dividend Yield	None

ABOUT

Cardiol Therapeutics Inc

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

CRDL.TO · Cardiol Therapeutics Inc

-

Cardiol Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Cardiol Therapeutics Inc using a moving average strategy